Inventor

HABEREY MARTIN

DE39 patents

⚠️ This page may combine multiple inventors who share the name “HABEREY MARTIN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

HABEREY MARTIN

SCHERING AG

20-methyl-substituted vitamin D derivatives

23-oxa-derivatives in the vitamin D series, process for their production, pharmaceutical preparations containing these derivatives as well as their use pharmaceutical agents

N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF

Vitamin D derivatives with phosphorus atoms in the side chains

Vitamin D derivatives with substituents at C-25, process for their production, intermediate products and use for the production of pharmaceutical agents

Vitamin D derivatives with C-25 substituents, process for their preparation, intermediate products and their use in preparing medicaments

22-en-25-oxa derivatives in the vitamin D series, process for their production, pharmaceutical preparations containing these derivatives as well as their use as pharmaceutical agents

20-position modified pharmaceutically active vitamin D series compounds

25-Carboxylic acid derivatives in the vitamin D series, process for their production, intermediate products for these processes, pharmaceutical preparations containing these derivatives as well as their use for the production of pharmaceutical agents

Cyanoanthranilamide derivatives and the use thereof as medicaments

VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones

Anthranyl amides and their use as medicaments

VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines

Vitamin D derivatives modified in the 20-position and pharmaceutical compositions thereof

N-oxide anthranylamide derivatives and their use as medicaments

Ortho-substituted anthranilic acid amides and their use as medicaments

Vitamin D derivatives with carbo- or heterocyclic substituents at C-25, a process for their production, intermediate products and their use for producing medicaments

Vitamin D derivatives with carbo- or heterocyclic substituents at C-25, process for their production, intermediate products and use for the production of pharmaceutical agents

Vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents

Novel carbacyclins, processes for their preparation and their use as medicinal agents

Vitamin D derivatives with carbo-or heterocyclic substituents at C-25, a process for their production, intermediate products and their use for producing medicaments

2,2:6,6-diethylen-3-oxo-17alpha-pregn-4-ene-21,17alpha-carbolactones, process for their production &amp; pharmaceutical preparations containing them

Vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents

Vitamin D derivatives with cyclopropyl rings in the lateral chains, a method and intermediate products for the production thereof and the utilization thereof for producing medicaments

Novel carbacyclins, process for the preparation thereof, and their use as medicinal agents

Certain prostacyclins and their blood-pressure-lowering and thrombocyte-aggregation-inhibiting compositions and methods

Substituted N-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl) derivatives, their production and use as pharmaceutical agents

20-alkyl-7-oxoprostacyclin derivatives useful as pharmaceuticals

5-fluorocarbacyclins, their preparation and pharmaceutical use

BAYER SCHERING PHARMA AG

VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines

Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors

Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors

VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines

Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors

NOVARTIS AG

VEGF receptor tyrosine kinase inhibitors

VEGF receptor tyrosine kinase inhibitors

Anthranylalkyl and cycloalkyl amides and use thereof as VEGF receptor inhibitors

Azanthranylalkyl and -cycloalkyl amides and their use as VEGF receptor inhibitors

SCHERING AKTIENGELLSCHAFT

Vitamin D derivatives with carbo- or heterocyclic substituents at C-25, a process for their production, intermediate products and their use for producing medicaments

2,2:6,6-diethylen-3-oxo-17alpha-pregn-4-ene-21,17alpha-carbolactones, process for their production & pharmaceutical preparations containing them